Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
27 sept. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Monthly information on share capital and company voting rights
05 sept. 2023 16h30 HE
|
Cellectis Inc.
PARIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of...
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
07 août 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
07 août 2023 07h00 HE
|
Marker Therapeutics
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination
07 août 2023 05h00 HE
|
First Light Acquisition Group
RESTON, Va., Aug. 07, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (“FLAG”) (NYSE American: FLAG), a special purpose acquisition company, today announced that the U.S. Securities and...
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
03 août 2023 16h30 HE
|
Cellectis Inc.
Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at the EHA annual meeting Clinical trials ongoing: BALLI-01 (evaluating UCART22),...
Monthly information on share capital and company voting rights
01 août 2023 16h30 HE
|
Cellectis Inc.
PARIS, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
27 juil. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
12 juil. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
Hematopoietic Stem Cells Transplantation Market revenue to cross USD 3.12 Billion by 2035, says Research Nester
10 juil. 2023 07h30 HE
|
Research Nester
New York, July 10, 2023 (GLOBE NEWSWIRE) -- The global hematopoietic stem cells transplantation market is estimated to grow at a CAGR of ~10% from 2023 to 2035. The market is estimated to garner a...